Clinical Safety and Feasibility Study Initiated Using Adipose Stem and Regenerative Cells in Breast Reconstruction Procedures

Source: Business Wire
Posted: April 20, 2006

SAN DIEGO & TOKYO--(BUSINESS WIRE)--April 20, 2006--Cytori Therapeutics, Inc. (NASDAQ:CYTX) (Frankfurt:XMPA) announced today approval to begin an investigator-initiated safety and feasibility study in Japan using adult adipose (fat) derived stem and regenerative cells for breast reconstruction.